Literature DB >> 6262973

The kissing virus.

M Haire.   

Abstract

Mesh:

Substances:

Year:  1981        PMID: 6262973      PMCID: PMC2386028     

Source DB:  PubMed          Journal:  Ulster Med J        ISSN: 0041-6193


× No keyword cloud information.
  9 in total

1.  The transmission of infectious mononucleosis.

Authors:  R J HOAGLAND
Journal:  Am J Med Sci       Date:  1955-03       Impact factor: 2.378

2.  Epstein-Barr virus-related serology in Hodgkin's disease.

Authors:  W Henle; G Henle
Journal:  Natl Cancer Inst Monogr       Date:  1973-05

3.  Oropharyngeal excretion of Epstein-Barr virus by renal transplant recipients and other patients treated with immunosuppressive drugs.

Authors:  B Strauch; L L Andrews; N Siegel; G Miller
Journal:  Lancet       Date:  1974-02-16       Impact factor: 79.321

4.  Raised antibody titres to E.B. virus in systemic lupus erythematosus.

Authors:  A S Evans; N F Rothfield; J C Niederman
Journal:  Lancet       Date:  1971-01-23       Impact factor: 79.321

5.  Epstein Barr virus nuclear antigen positive lymphoma after cyclosporin A treatment in patient with renal allograft.

Authors:  D H Crawford; J A Thomas; G Janossy; P Sweny; O N Fernando; J F Moorhead; J H Thompson
Journal:  Lancet       Date:  1980-06-21       Impact factor: 79.321

6.  Epstein-Barr virus--oncogen or mitogen?

Authors:  R S Schwartz
Journal:  N Engl J Med       Date:  1980-06-05       Impact factor: 91.245

7.  Epstein-Barr virus-related serology in marrow transplant recipients.

Authors:  B Lange; W Henle; J D Meyers; L C Yang; C August; P Koch; A Arbeter; G Henle
Journal:  Int J Cancer       Date:  1980-08       Impact factor: 7.396

8.  The suppression of Epstein-Barr virus infection in vitro occurs after infection but before transformation of the cell.

Authors:  D A Thorley-Lawson
Journal:  J Immunol       Date:  1980-02       Impact factor: 5.422

9.  Epstein-Barr-virus-induced oncogenesis in immune-deficient individuals.

Authors:  D T Purtilo
Journal:  Lancet       Date:  1980-02-09       Impact factor: 79.321

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.